Diane Retallack
About Diane Retallack
Diane Retallack serves as the Senior Vice President of Platform Technologies and Innovations at Ligand Pharmaceuticals, where she has worked since 2021. She has extensive experience in research and development, having previously held leadership roles at The Dow Chemical Company and Pfenex Inc.
Current Role at Ligand Pharmaceuticals
Diane Retallack serves as Senior Vice President of Platform Technologies and Innovations at Ligand Pharmaceuticals, a position she has held since 2021. In this role, she guides a team within the Pelican Expression Technology Business Unit. Her responsibilities include overseeing the development and implementation of innovative platform technologies that enhance the company's product offerings. Additionally, she actively manages the intellectual property strategy, which encompasses patent and trademark matters, ensuring that Ligand Pharmaceuticals maintains a competitive edge in the biotechnology sector.
Previous Experience at Pfenex Inc
Before joining Ligand Pharmaceuticals, Diane Retallack worked at Pfenex Inc for several years. She held the position of Director of Upstream Processing and Intellectual Property from 2009 to 2016, where she focused on developing upstream processes for biopharmaceutical production. She later served as Vice President of Upstream Process Development & Intellectual Property from 2019 to 2020, further advancing her expertise in process development and intellectual property management within the biotechnology field.
Experience at The Dow Chemical Company
Diane Retallack began her career at The Dow Chemical Company, where she worked as an R&D Leader from 2000 to 2009. During her nine years at Dow, she contributed to various research and development initiatives, enhancing her skills in innovation and technology development. This experience laid the foundation for her subsequent roles in the biotechnology industry.
Educational Background
Diane Retallack earned her Doctor of Philosophy in Microbiology and Immunology from the University of Michigan, completing her studies from 1990 to 1995. Prior to that, she obtained a Bachelor of Science in Biology from Widener University, where she studied from 1986 to 1990. Her educational background provides a strong foundation for her work in the biotechnology and pharmaceutical sectors.